Effects and clinical efficacy of breviscapine on inflammatory factors and coagulation function in patients with septic acute lung injury

doi:10.11958/20221250

Abstract

Abstract:

Objective To explore effects and clinical efficacy of breviscapine on inflammatory factors and coagulation function in patients with septic acute lung injury (ALI). Methods A total 84 patients with ALI caused by sepsis were assigned to the control group, the low-dose breviscapine group (low-dose group) and the high-dose breviscapine group (high-dose group) according to random digital table, with 28 cases in each group. The control group was treated with conventional Western medicine. The low-dose group was additionally given breviscapine injection (20 mg, one time/d) on the basis of the control group, and the high-dose group was additionally given breviscapine injection (40 mg, one time/d) on the basis of the control group. The three groups were treated for 2 weeks. The clinical efficacy were evaluated in the three groups. Traditional Chinese medicine (TCM) syndrome scores, oxygenation index (PaO₂/FiO₂), interleukin (IL) -6 and tumor necrosis factor-α (TNF-α) levels, prothrombin time (PT), activated partial thromboplastin time (APTT) and platelet count were compared before and after two weeks of treatment between the three groups. Drug-related adverse events during treatment were recorded in each group. Results The clinical efficacy and total effective rate were better in the low-dose group and the high-dose group compared with those of the control group (P<0.05). After treatment, the TCM syndrome score and levels of IL-6 and TNF-α were decreased than those before treatment in the three groups (P<0.05), and the control group, the low-dose group and the high-dose group were decreased successively. After treatment, PT and APTT were prolonged compared with those before treatment in the three groups, and the control group, the low-dose group and the high-dose group were prolonged successively (P<0.05). After treatment, PaO₂/FiO₂ and platelet count were increased compared with those before treatment in the three groups, and the control group, the low-dose group and the high-dose group were increased successively (P<0.05). There were no severe adverse drug events during the treatment in the three groups. Conclusion Breviscapine can significantly improve the coagulation dysfunction in sepsis, reduce the abnormal consumption of platelets, inhibit inflammatory response, and has a relatively definite clinical effect on patients with sepsis-induced acute lung injury.

Key words: sepsis, inflammation, breviscapine, acute lung injury, coagulation function

CLC Number:

R631

Figures/Tables 6

References 21

[1]	WANG X, XING Y, TANG Z, et al. Thioredoxin-2 impacts the inflammatory response via suppression of NF-κB and MAPK signaling in sepsis shock[J]. Biochem Biophys Res Commun, 2020, 524(4):876-882. doi:10.1016/j.bbrc.2020.01.169.
[2]	周醒, 谢剑锋, 杨毅. 脓毒症相关凝血功能障碍的机制及药物治疗进展[J]. 中华内科杂志, 2022, 61(2):224-228.
	ZHOU X, XIE J F, YANG Y. Mechanism and treatment progress for sepsis-induced coagulopathy[J]. Chinese Journal of Internal Medicine, 2022, 61(2):224-228. doi:10.3760/cma.j.cn112138-20210314-00212.
[3]	卢悦, 张平平, 王东强, 等. 急性肺损伤中医病因病机的探讨[J]. 中国中医急症, 2020, 29(2):280-282.
	LU Y, ZHANG P P, WANG D Q, et al. Discussion on pathogenesis and pathogenesis of acute lung injury[J]. Journal of Emergency in Traditional Chinese Medicine, 2020, 29(2):280-282. doi:10.3969/j.issn.1004-745X.2020.02.025.
[4]	李若愚, 肖超烈, 沈其猷, 等. 试论“瘀”在ARDS形成中的作用[J]. 光明中医, 2016, 31(15):2164-2165.
	LI R Y, XIAO C L, SHEN Q Y, et al. Discussion the function of “Blood Stasis” in the formation of ARDS[J]. Guangming Journal of Chinese Medicine, 2016, 31(15):2164-2165. doi:10.3969/j.issn.1003-8914.2016.15.010.
[5]	张海云, 韩伟东, 刘海梅, 等. 丹参酮ⅡA对急性肺损伤小鼠炎症因子和氧化应激水平的影响[J]. 解剖学研究, 2020, 42(6):491-495.
	ZHANG H Y, HAN W D, LIU H M, et al. Effects of Tanshinone ⅡA on inflammatory factors and oxidative stress in mice with acute lung injury[J]. Study of anatomy, 2020, 42(6):491-495. doi:10.3969/j.issn.1671-0770.2020.06.002
[6]	WU L H, LIU M, FANG Z Y. Combined therapy of hypertensive nephropathy with breviscapine injection and antihypertensive drugs:a systematic review and a meta-analysis[J]. Evid Based Complement Alternat Med, 2018, 2018:2958717. doi:10.1155/2018/2958717.
[7]	李慧, 任小瑞, 张育建, 等. 活血化瘀中药注射剂治疗慢性阻塞性肺疾病急性加重期网状Meta分析[J]. 辽宁中医药大学学报, 2022, 24(2):120-127.
	LI H, REN X R, ZHANG Y J, et al. Network Meta-analysis of promoting blood circulation and removing blood stasis chinese medicine injections on acute exacerbation of chronic obstructive pulmonary disease[J]. Journal of Liaoning University of Traditional Chinese Medicine, 2022, 24(2):120-127. doi:10.13194/j.issn.1673-842x.2022.02.027.
[8]	SINGER M, DEUTSCHMAN C S, SEYMOUR C W, et al. The third international consensus definitions for sepsis and septic shock sepsis-3[J]. JAMA, 2016, 315(8):801-810. doi:10.1001/jama.2016.0287.
[9]	ARDS Definition Task Force, MARCO V R, GORDON D R, et al. Acute respiratory distress syndrome:the Berlin Definition[J]. JAMA, 2012, 307(23):2526-2533. doi:10.1001/jama.2012.5669.
[10]	国家中医药管理局医政局. 中医病证诊断疗效标准(2017版)[M]. 北京: 中国中医药出版社, 2017:3-4.
	National Administration of Traditional Chinese Medicine. Diagnostic efficacy criteria for Diseases and Syndromes of Traditional Chinese Medicine (2017 edition)[M]. Beijing: China Traditional Chinese Medicine Publishing House, 2017:3-4.
[11]	孙传兴. 临床疾病诊断依据治愈好转标准[M]. 北京人民军医出版社, 2002:126.
	SUN C X. Clinical disease diagnosis is based on cure and improvement criteria[M]. Beijing: Beijing People's Military Medical Publishing House, 2002:126.
[12]	黄蓓. 《证候类中药新药临床研究技术指导原则》发布[J]. 中医药管理杂志, 2018, 26(21):107.
	HUANG B. Technical guidelines for clinical research of new syndromic TCM drugs[J]. Journal of Traditional Chinese Medicine Management, 2018, 26(21):107. doi:10.16690/j.cnki.1007-9203.2018.21.056.
[13]	IBA T, LEVI M, LEVY J H. Sepsis-induced coagulopathy and disseminated intravascular coagulation[J]. Semin Thromb Hemost, 2020, 46(1):89-95. doi:10.1055/s-0039-1694995.
[14]	陈振华, 江琴. 脓毒症患者凝血功能指标、降钙素原水平与临床预后的关系[J]. 检验医学, 2020, 35(10):1053-1055.
	CHEN Z H, JIANG Q. Relationship between coagulation function index,procalcitonin level and clinical prognosis in patients with sepsis[J]. Laboratory medicine, 2020, 35(10):1053-1055. doi:10.3969/j.issn.1673-8640.2020.10.021.
[15]	蒋湘粤, 冯芮华, 刘江萍, 等. 低分子肝素对急性呼吸窘迫综合征患者临床疗效影响的Meta分析[J]. 中华危重病急救医学, 2020, 32(12):1472-1478.
	JIANH X Y, FENG R H, LIU J P, et al. Meta-analysis of the curative effect of low molecular weight heparin on acute respiratory distress syndrome[J]. Chinese Critical Care Medicine, 2020, 32(12):1472-1478. doi:10.3760/cma.j.cn121430-20201019-01426.
[16]	李桂云, 冯永文, 向兰, 等. 不同预后脓毒症患者血清降钙素原、C反应蛋白与凝血功能指标和APACHEⅡ评分的关系分析[J]. 现代生物医学进展, 2021, 21(2):274-278.
	LI G Y, FENG Y W, XIANG L, et al. Analysis of the relationship between serum procalcitonin,c-reactive protein and coagulation function and APACHEⅡscore in sepsis patients with different prognosis[J]. Progress in Modern Biomedicine, 2021, 21(2):274-278. doi:10.13241/j.cnki.pmb.2021.02.016.
[17]	刘继法, 胡渊龙, 邱占军, 等. 中药有效成分治疗脓毒症急性肺损伤作用机制研究进展[J]. 辽宁中医药大学学报, 2021, 23(1):171-176.
	LIU J F, HU Y L, QIU Z J, et al. Advances in the pathogenesis of active ingredients of traditional chinese medicine in the treatment of acute lung injury in sepsis[J]. Journal of Liaoning University of Traditional Chinese Medicine, 2021, 23(1):171-176. doi:10.13194/j.issn.1673-842x.2021.01.040.
[18]	余霞. 成人呼吸窘迫综合征病理分期的中医治疗思路[J]. 中医药学刊, 2003, 21(10):1760-1792.
	YU X. TCM treatment of adult respiratory distress syndrome by pathological stages[J]. Journal of Chinese Medicine, 2003, 21(10):1760-1792. doi:10.3969/j.issn.1673-7717.2003.10.094.
[19]	孙瑞华, 李欢, 徐凯, 等. 中医证候临床评价的探讨[J]. 世界中医药, 2017, 12(6):1470-1474.
	SUN R H, LI H, XU K, et al. Clinical evaluation in Traditional Chinese Medicine (TCM)[J]. WORLD CHINESE MEDICINE, 2017, 12(6):1470-1474. doi:10.3969/j.issn.1673-7202.2017.06.063.
[20]	韩宇, 高传玉, 秦秉, 等. 抗凝治疗对脓毒症凝血和炎症指标的影响及其意义[J]. 中华危重病急救医学, 2015, 27(2):102-105.
	HAN Y, GAO C Y, QIN B, et al. The effect of anticoagulant therapy on coagulation and inflammation markers in sepsis patients and its significance[J]. Chinese Critical Care Medicine, 2015, 27(2):102-105. doi:10.3760/cma.j.issn.2095-4352.2015.02.005.
[21]	WALBORN A, RONDINA M, MOSIER M, et al. Endothelial dysfunction is associated with mortality and severity of coagulopathy in patients with sepsis and disseminated intravascular coagulation[J]. Clin Appl Thromb Hemost, 2019, 25:1-9. doi:10.1177/1076029619852163.

组别	性别（男/女）	年龄（岁）	APACHEⅡ（分）	Murry肺损伤评分（分）	感染部位^＃（例）
对照组	16/12	70.11±7.09	24.43±2.67	2.89±0.34	11/7/4/3/3
灯低组	14/14	72.04±6.32	23.86±2.79	2.83±0.37	10/8/5/3/2
灯高组	15/13	69.54±6.71	25.11±2.42	2.93±0.41	12/6/4/4/2
F或χ²	0.287	1.066	1.583	0.661	1.482

组别	性别（男/女）	年龄（岁）	APACHEⅡ（分）	Murry肺损伤评分（分）	感染部位^＃（例）
对照组	16/12	70.11±7.09	24.43±2.67	2.89±0.34	11/7/4/3/3
灯低组	14/14	72.04±6.32	23.86±2.79	2.83±0.37	10/8/5/3/2
灯高组	15/13	69.54±6.71	25.11±2.42	2.93±0.41	12/6/4/4/2
F或χ²	0.287	1.066	1.583	0.661	1.482

组别	显效	有效	无效	总有效
对照组	4（14.29）	13（46.43）	11（32.14）	17（60.71）
灯低组	7（21.43）	16（60.71）	5（17.86）	23（82.14）
灯高组	8（25.00）	17（64.29）	3（10.71）	25（89.29）
χ²	6.085^*			6.582^*

组别	显效	有效	无效	总有效
对照组	4（14.29）	13（46.43）	11（32.14）	17（60.71）
灯低组	7（21.43）	16（60.71）	5（17.86）	23（82.14）
灯高组	8（25.00）	17（64.29）	3（10.71）	25（89.29）
χ²	6.085^*			6.582^*

组别	治疗前	治疗后	t
对照组	14.32±2.25	11.79±2.67	7.392^**
灯低组	14.75±2.19	9.86±2.73^a	23.534^**
灯高组	15.07±2.14	7.43±2.38^ab	38.052^**
F	0.825	16.843^**